Vaxart Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Steven Lo

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	3.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Steven Lo (57 yo)

less than a year

Permanencia

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sean Tucker	Senior VP & Chief Scientific Officer	14.9yrs	US$1.14m	0.10% MX$ 4.5m
James Cummings	Chief Medical Officer	3.4yrs	US$1.17m	0.063% MX$ 2.8m
Steven Lo	President	less than a year	sin datos	sin datos
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	2.1yrs	sin datos	0.041% MX$ 1.8m
Raymond Stapleton	Chief Technology Officer	2.4yrs	sin datos	sin datos
Edward Berg	Senior VP & General Counsel	2.9yrs	sin datos	0.050% MX$ 2.2m
Shaily Garg	Senior Vice President of Clinical Development & Project Management	4.8yrs	sin datos	sin datos
Rajesh Kapoor	Senior Vice President of Quality	4yrs	sin datos	sin datos

3.2yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VXRT * se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Lo	President	less than a year	sin datos	sin datos
Robert Yedid	Independent Director	5.3yrs	US$92.26k	0.0081% MX$ 353.4k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos
Elaine Heron	Independent Director	2.4yrs	US$89.08k	0.011% MX$ 469.4k
Michael Finney	Independent Chairman of the Board	6.9yrs	US$109.57k	0.29% MX$ 12.8m
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos
David Wheadon	Independent Director	3.8yrs	US$93.72k	0.0065% MX$ 281.7k
Robert Belshe	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos
William Watson	Independent Director	2.4yrs	US$94.76k	0.023% MX$ 999.3k
Marion Pepper	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos
Ralph Baric	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos
Gregory Gray	Member of Scientific & Clinical Advisory Board	3.4yrs	sin datos	sin datos

3.4yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de VXRT * se considera experimentada (3.4 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/01/07 21:05
Precio de las acciones al final del día	2024/12/23 00:00
Beneficios	2024/09/30
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

Vaxart, Inc. está cubierta por 6 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Mayank Mamtani	B. Riley Securities, Inc.
Charles Duncan	Cantor Fitzgerald & Co.
Vernon Bernardino	H.C. Wainwright & Co.

Vaxart Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently bought Mex$250k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Recent updates

Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance Update

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023)

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Independent Director recently bought Mex$250k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023)

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Less than half of directors are independent

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

High number of new and inexperienced directors

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

High number of new and inexperienced directors

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

High number of new and inexperienced directors

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Director recently bought Mex$294k worth of stock

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

High number of new and inexperienced directors

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

High number of new and inexperienced directors

Key Executive recently bought Mex$322k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

High number of new and inexperienced directors

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Vaxart, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2021)

No longer forecast to breakeven

High number of new and inexperienced directors

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

High number of new and inexperienced directors

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

High number of new and inexperienced directors

Forecast to breakeven in 2024

Forecast to breakeven in 2024

High number of new and inexperienced directors

High number of new and inexperienced directors